survival: hazard ratio for high ED 0.64, 95% CI 0.40-1.01, P=0.055. Among patients not receiving a BB, low HR showed a trend for better outcome: hazard ratio 0.79, 0.62-1.02, P=0.07. By contrast, HR seemed to play a minor role in predicting survival in subgroups treated with a high ED (P=0.83) or a low ED (P=0.26). Of note, after additional adjustment for body weight (BW), BB treatment per se continued to predict outcome, whereas ED did not (figure, right; both P>0.5). Excluding subjects with LVEF >45% from the analysis yielded similar results. Conclusion: In heart failure patients it is of primary importance to start BB therapy if tolerated and not contraindicated. Rather than focusing on maximal target dose, BB uptitration should target on HR, possibly including other measures if BB is not tolerated. Background: After successful surgery for valvular heart disease, symptoms and cardiac function are in general greatly improve. Nevertheless, left ventricle dysfunction and heart failure symptoms may persist and worsen postoperatively. We hypothesized that the metabolically acting agent trimetazidine would help improve symptoms and cardiac function after valve replacement. Methods: In a randomized, open-label, case-control 1-year study, trimetazidine (35 mg twice daily) was added to optimal standard therapy (vitamin K antagonists, ACEIs/ARBs, beta-blockers, diuretics, statins, and digoxin) 2-4 weeks after conventional aortic/mitral valve replacement. Efficacy endpoints included changes from preoperative baseline in 6-min walk distance (6-MWD), New York Heart Association (NYHA) functional class, hemodynamic parameters, heart failure hospitalizations, and all-cause mortality. Results: 120 patients [mean (SE) age 53.2 (2.1) years, 72 males (60%), 48 females (40%)] with mechanical prosthesis of aortic (n=64) and mitral (n=56) valve [48 due to degenerative (40%), 42 rheumatic (35%), 12 myxomatous (10%), 10 congenital valve diseases (8.3%) and 8 infectious endocarditis (6.7%); 65% NYHA class III, 35% NYHA class II; 20% concomitant CABG; median (IQR) 6-MWD 329 (162-420) m; mean (SE) left ventricular ejection fraction (LVEF) 59.6 (2.8)%] were randomized. There were no significant differences between trimetazidine and control group at baseline. At month 12, patients receiving trimetazidine (n=60) had a mean increase in 6-MWD of 156 m (p<0.0001); control patients (n=60) had a mean 6-MWD increase of 121 m (p=0.0005), with a control-adjusted difference of +35 m (p=0.041). NYHA status improved by two classes in 40% of trimetazidine versus 21.7% of controls (p=0.035), by one class in 60% versus 78.3% (p=0.035). Trimetazidine delayed the time to clinical worsening (p=0.0202) and reduced the heart failure admissions (p=0.0045). Improvements were noted in control-adjusted changes in postoperative heart remodelling, e.g. in mean LVEF (+3.8%; p=0.003), left ventricular end-diastolic diameter (-5.6 mm; p=0.001), and end-systolic diameter (-3.7 mm; p=0.004). Combination therapy with trimetazidine was well tolerated. No a patient died in the trimetazidine group, as compared with one patient in the control group (p=0.89). Conclusions: Long-term trimetazidine therapy for patients with mechanical aortic/mitral valve prostheses improves symptom status and cardiac function. This study supports the hypothesis of clinical benefits from continued metabolic trimetazidine in surgically corrected valvular heart disease.
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Early and delayed IL-1 beta modulating antibody, gevokizumab, treatments limit cardiac remodeling and reverse coronary endothelial dysfunction following myocardial infarction injury in diabetic rats N Aims: Cardiac interleukin-1 beta (IL1-β) production is enhanced acutely after myocardial infarction and is involved in myocardial damages. We tested if early and delayed IL1-β modulation by IL-1β modulating antibody, gevokizumab, prevent left ventricular (LV) remodeling and endothelial dysfunction induced by LV ischemia/reperfusion (I/R) in diabetic rats (GK). Methods: Gevokizumab (Gevo; 10 mg/kg) was administered 1 hour (early) or 7
Abstract P3291 - (Table) . At 90 days, early, delayed Gevo and perindopril limited in a similar manner, the LV late dilatation, the reduction of FS and LV systolic and diastolic dysfunction induced by I/R (Table) . At 90 days, GK coronary endothelium-dependent relaxation to acetylcholine was impaired by I/R (59±13 vs. 17±4%, p<0.05). Early, delayed Gevo and perindopril prevented (86±4, 92±2 and 98±1% respectively; p<0.05 vs GK+I/R) coronary endothelial dysfunction.
Conclusion:
In a clinically relevant model of I/R, the IL-1β modulating antibody, gevokizumab, started early or late after myocardial reperfusion exerts beneficial cardiovascular effects.
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Delayed Wnt/frizzled inhibition suppresses left ventricular remodeling and heart failure development following myocardial infarction Purpose: Current pharmacological therapy cannot prevent left ventricular (LV) remodeling that follows myocardial infarction (MI), but intervenes mostly symptomatically. Our group has previously shown that LV dilatation can be attenuated and heart failure (HF) development can be prevented by pharmacological Wnt/frizzled signaling blockade with UM206, when treatment is started immediately after MI induction. The aim of the present study was to investigate whether UM206 treatment initiated 3 weeks after MI (when LV dilatation has started developing) can have analogous beneficial effects. Methods: Swiss male mice were subjected to MI by left anterior descending (LAD) coronary artery permanent ligation. At week 3 post-MI, animals were divided into 2 groups, group I (n=9) treated with UM206 (via an Alzet osmotic minipump, 6μg/kg/day) and group II (n=6) treated with saline (control, also via an osmotic minipump). Treatment was continued until week 8 post-MI, when animals were sacrificed. Cardiac function and geometry data were obtained using 3D-echocardiography (Vevo 2100, Visualsonics, Toronto, Canada). Results: Both End diastolic volume (EDV, saline: 278±24 mm 3 , UM206: 202±13 mm 3 ; p<0.01) and End systolic volume (ESV, saline: 250±27 mm 3 , UM206: 151±15 mm 3 ; p<0.01) were improved by the delayed treatment with UM206. Moreover, UM206 treatment exhibited a beneficial effect on Ejection Fraction (EF) (saline: 11.0±3.2%, UM206: 23.2±2.6%; p<0.05), while raised lung weights (an indication of HF development) were found in the saline-treated animals only (saline: 319±42 mg, UM206: 214±6 mg, p<0.01). Myofibroblast count in the infarct area was not found to be increased in the UM206-treated group; MMP-2 protein levels were suppressed in the UM206-treated animals, 8 weeks post-MI (MMP-2/GAPDH, saline: 0.13±0.05 vs UM206: 0.05±0.01). Conclusion: Administration of UM206 starting at week 3 post-MI, has a cardioprotective effect, as it suppresses further increases of EDV and ESV and preserves the EF. This leads to overall enhanced cardiac function and prevention of HF development, even after adverse LV remodeling had been initiated. These beneficial effects of Wnt/frizzled blockade do not appear to be mediated via direct effects on myofibroblasts but potentially via MMP-2 inhibition, leading to increased ECM deposition.
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Zofenopril is a cost-effective treatment for patients with left ventricular systolic dysfunction following acute myocardial infarction: a pharmacoeconomic analysis of the SMILE-4 study 
